The trial was testing the drug, selonsertib, in patients with a form
of fibrosis, called bridging, caused by NASH or Nonalcoholic
The drug did not show an improvement in fibrosis symptoms, Gilead
The company in February said selonsertib had failed another trial
testing patients with compensated cirrhosis, an advanced form of
[to top of second column]
Analysts have projected the market for NASH treatments to reach $20
billion to $35 billion as people with fatty diets increasingly
develop the disease.
Fat accumulation and inflammation from NASH can lead to scarring of
tissue, or fibrosis, that impairs liver function.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
[© 2019 Thomson Reuters. All rights
Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.